Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials

PURPOSE: Interleukin-6 (IL-6) levels discriminate between patients with mild and severe COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a systematic review, meta-analysis, trial sequential analysis (TSA), and meta-regression of randomized-controlled trials to ascert...

Descripción completa

Detalles Bibliográficos
Autores principales: Snow, Timothy Arthur Chandos, Saleem, Naveed, Ambler, Gareth, Nastouli, Eleni, Singer, Mervyn, Arulkumaran, Nishkantha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139226/
https://www.ncbi.nlm.nih.gov/pubmed/34019122
http://dx.doi.org/10.1007/s00134-021-06416-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139226/
https://www.ncbi.nlm.nih.gov/pubmed/34019122
http://dx.doi.org/10.1007/s00134-021-06416-z

Ejemplares similares